ImmuCell Corporation (ICCC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $103.82M
Last updated: Nov 17, 2026 at 4:10 PM ET
ImmuCell Corporation (ICCC) Statistics
ImmuCell (ICCC) has a market cap of $103.82M and an enterprise value of $103.81M. Its trailing P/E is 56.7x.
Total Valuation
Enterprise value is 0.01% below the market cap, as cash exceeds debt.
| Market Cap | $103.82M |
|---|---|
| Enterprise Value | $103.81M |
| Latest price (Nov 17, 2026) | $11.33 |
Key Dates
The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.1x and 3.1x.
| P/E Ratio | 56.7x |
|---|---|
| P/S Ratio | 3.1x |
| P/B Ratio | 3.1x |
| P/TBV Ratio | 3.1x |
| P/FCF Ratio | 19.1x |
| P/OCF Ratio | 13.3x |
Enterprise Valuation
Counting debt and cash, the company is valued at 25.1x EBITDA and 19.1x free cash flow.
| EV / Earnings | 55.2x |
|---|---|
| EV / Sales | 3.1x |
| EV / EBITDA | 25.1x |
| EV / EBIT | 53.9x |
| EV / FCF | 19.1x |
Price Statistics
The stock is up 109.81% over 52 weeks and trades 11.52% above its 50-day average.
| Beta (1Y) | 0.31 |
|---|---|
| 52-Week Change | +109.81% |
| 1-Month Change | +7.80% |
| 3-Month Change | +11.85% |
| 6-Month Change | +11.08% |
| 5-Year Change | +16.59% |
| 10-Year Change | +83.54% |
| Total Return (1Y) | +109.81% |
| Total Return (3Y CAGR) | +33.50% |
| Total Return (5Y CAGR) | +4.88% |
| Return vs SPY (1Y) | +136.91% |
| Max Drawdown (1Y) | -18.26% |
| Max Drawdown (3Y) | -40.00% |
| Sharpe Ratio (1Y) | 1.91 |
| Correlation with SPY (1Y) | 0.09 |
| 50-Day Average | $10.16 |
| 200-Day Average | $9.11 |
| 52-Week Range | $4.52 to $12.10 |
| RSI (14 Days) | 65.7 |
| Average Volume (20 Days) | 13.42K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.61x current liabilities, and total debt is 0.24x shareholder equity.
| Current Ratio | 4.61x |
|---|---|
| Quick Ratio | 2.50x |
| Debt / Equity | 0.24x |
| Debt / EBITDA | 1.93x |
| Debt / FCF | 1.46x |
Returns and Efficiency
Return on invested capital is 4.62% over the last 12 months, against a 5-year average of -6.08%.
| Return on Equity (ROE) | 5.74% |
|---|---|
| Return on Assets (ROA) | 3.92% |
| Return on Invested Capital (ROIC) | 4.62% |
| Return on Capital Employed (ROCE) | 4.45% |
| ROE (5Y Average) | -8.65% |
| ROA (5Y Average) | -5.23% |
| ROIC (5Y Average) | -6.08% |
| Asset Turnover | 0.71x |
| Inventory Turnover | 2.08x |
| Receivables Turnover | 10.59x |
| Cash Conversion Cycle | 155 days |
Taxes
Income tax took 2.31% of pretax income over the last 12 months.
| Income Tax (TTM) | $44.54K |
|---|---|
| Effective Tax Rate | 2.31% |
Scores
ICCC has an Altman Z-Score of 5.01, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 5.01 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $33.21M over the last 12 months is up 19.59% from the 12 months before.
| Revenue | $33.21M |
|---|---|
| Revenue Growth (YoY) | +19.59% |
| Gross Profit | $13.56M |
| Operating Income | $4.80M |
| Pretax Income | $1.92M |
| Net Income | $1.88M |
| EBIT | $1.92M |
| Reported EPS (TTM) | $0.20 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 68.33% of the $47.96M in total assets.
| Cash and Equivalents | $7.91M |
|---|---|
| Total Debt | $7.90M |
| Net Cash | $15.56K |
| Net Cash Per Share | $0.00 |
| Working Capital | $16.90M |
| Shareholder Equity | $32.77M |
| Book Value Per Share | $3.61 |
| Tangible Book Value | $32.68M |
| Tangible Book Per Share | $3.60 |
| Total Assets | $47.96M |
| Total Liabilities | $15.18M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $2.43M of capital spending, operating cash flow left $5.40M of free cash flow.
| Operating Cash Flow | $7.83M |
|---|---|
| Capital Expenditures | $2.43M |
| Free Cash Flow | $5.40M |
| FCF Per Share | $0.59 |
| Depreciation and Amortization | $2.18M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 14.47%, against a 5-year average of -8.83%.
| Gross Margin | 40.83% |
|---|---|
| Operating Margin | 14.47% |
| Pretax Margin | 5.79% |
| Net Margin | 5.66% |
| EBIT Margin | 5.79% |
| FCF Margin | 16.27% |
| Gross Margin (5Y Average) | 35.94% |
| Operating Margin (5Y Average) | -8.83% |
| Net Margin (5Y Average) | -11.76% |
Growth
Revenue grew 14.19% a year over 3 years.
| Revenue Growth (3Y CAGR) | +14.19% |
|---|---|
| Revenue Growth (5Y CAGR) | +12.50% |
| Book Value Per Share Growth (2Y CAGR) | -3.70% |
| Tangible Book Per Share Growth (2Y CAGR) | -3.61% |
Dividends and Yields
ICCC does not pay a dividend. Its free cash flow yield is 5.25%.
| Earnings Yield | 1.76% |
|---|---|
| FCF Yield | 5.25% |
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.00% |
Peer Position
Against 6 similar companies, ICCC has the 5th highest P/S.
P/S RatioPeer median 17.4x
ROICPeer median -147.29%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -64.32%
| P/S Ratio | 3.1x vs 17.4x median |
|---|---|
| ROIC | 4.62% vs -147.29% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +19.59% vs -64.32% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ICCC
What is ICCC's market cap?
ImmuCell has a market cap of $103.82M. Its enterprise value, which adds debt and subtracts cash, is $103.81M.
What is ICCC's P/E ratio?
ImmuCell has a trailing P/E ratio of 56.7x.
How many shares of ICCC are outstanding?
ImmuCell has 9.08M shares outstanding. The count is up 0.43% from a year earlier.
Does ICCC pay a dividend?
No. ImmuCell does not pay a dividend.
How much debt does ICCC have?
ImmuCell has $7.90M of total debt and $7.91M of cash and equivalents, a net cash position of $15.56K.
ICCC pages: Overview, Charting, Earnings, Financials, Statistics, Valuation, Competitors